Amylyx reveals full data that drove pivotal failure for ALS drug: #AAN24
Amylyx outlined the scope of its Phase 3 defeat, demonstrating the extent to which its now-withdrawn ALS drug Relyvrio failed to separate itself from placebo.
In the primary endpoint measuring patients’ declining levels of function, known as the ALSFRS-R, Relyvrio induced only a 0.343-point difference between the trial’s active and placebo arms after 48 weeks, according to Amylyx’s presentation on Tuesday at the American Academy of Neurology’s annual meeting.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
